# US 2012/0251624 A1 · Novel inhibitors of arachidonic acid formation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251624 A1
- Document ID: US20120251624A1
- Status: Published application
- Kind: A1
- Application number: 13/315,359
- Filed: 2011-12-09
- Published: 2012-10-04
- Earliest claimed: 2006-02-06
- Inventors: Barry D. SEARS
- Web page: https://patentgrep.com/patent/US20120251624A1

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/75: of ethene
- A61K 31/77: of oxiranes
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

## Claims

### Claim 1

A method for reducing the level of arachidonic acid produced by Δ-5-desaturase (D5D) in a mammal, the method comprising administering to a mammal a composition comprising a non-toxic derivative of sesamol, wherein the non-toxic derivative of sesamol is an acylated sesamol.

### Claim 2 (depends on 1)

The method of claim 1, wherein the acylated sesamol is obtained by reacting a sesamol compound with an activated carboxylic acid.

### Claim 3 (depends on 2)

The method of claim 2, wherein the activated carboxylic acid is an acid chloride, an acid anhydride, or obtained by reacting a carboxylic acid with 1,1 carbonyl diimidazole.

### Claim 4 (depends on 3)

The method of claim 3, wherein the activated carboxylic acid is an activated fatty acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the activated fatty acid comprises 2 to 22 carbon atoms.

### Claim 6 (depends on 4)

The method of claim 4, wherein the degree of unsaturation of the activated fatty acid ranges from 0 to 6.

### Claim 7 (depends on 4)

The method of claim 4, wherein the activated fatty acid is an activated derivative of palmitic acid, oleic acid, linoleic acid, alpha-linolenic acid, arachidic acid, gadoleic acid, 5,8,11,14,17-eicosapentaenoic acid, or 4,7,10,13,16,19-docosahexaenoic acid.

### Claim 8 (depends on 1)

The method of claim 1, wherein the non-toxic derivative of sesamol is sesamol oleate.

### Claim 9 (depends on 1)

The method of claim 1, wherein the activated carboxylic acid is an acid chloride or an acid anhydride of CH3O(CH2CH2O)nCH2C(O)OH, or obtained by reacting CH3O(CH2CH2O)nCH2C(O)OH with 1,1 carbonyl diimidazole, wherein n ranges from 2 to 400.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering step is carried out enternally or parenternally.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is prepared as a nutritional supplement in a form selected from the group consisting of a capsule, a bar, a tablet, a powder, and a beverage package.

### Claim 12 (depends on 1)

The method of claim 1, wherein the non-toxic derivative of sesamol is administered to the mammal in an amount that is effective to reduce the level of arachidonic acid in the mammal.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition further comprises a fish oil.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more proteins and one or more carbohydrates, wherein the proteins and the carbohydrates are present at a ratio of between about 0.5 and about 1.0.
